Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.46 |
| ▸ | CDC25B | P30305 | 8/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.46 |
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160114 | 1.00 | NT5E (0.53) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL7178488 | 0.89 | TSHR (0.46) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL7114420 | 0.89 | TSHR (0.46) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL19731824 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL4181388 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL8225871 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL2482599 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL18744567 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL18241576 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL20295300 | 0.87 | NT5E (0.51) | NT5ETACR2PTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211663-B2 | Synthesis of oligosaccharides, reagents and methods related thereto | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1119577-B1 | Synthesis of oligonucleotides, reagents and methods related thereto | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20030004322-A1 | Synthesis of oligosaccharides, reagents and methods related thereto | SEEBERGER PETER H (US) | 2003-01-02 | — | — | US | disclosed |
| US-6323339-B1 | GLYCOSYLATING SUBSTRATE IN PRESENCE OF LEWIS ACID; PURIFICATION; COMBINATORIAL CHEMISTRY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004322-A1 | Synthesis of oligosaccharides, reagents and methods related thereto | GPI, STT3A, UGCG | NT5E 228/4885TACR2 3859/4885PTPN1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.